EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Functional Analysis of DPYD Variants Associated With 5‐Fluorouracil‐Based Anticancer Drug Toxicity in Cancer Patients

Yuta Sudo, Yoko Nakajima, Katsuyuki Yokoi, Yasuaki Yasuda, Hidehito Inagaki, Hiroshi Matsuoka, Yasuhiro Maeda, Tetsushi Yoshikawa, Tetsuya Ito, Hiroki Kurahashi

Journal of Clinical Pharmacy and Therapeutics · 2026-01 · 2026 (1)

DOI: 10.1155/jcpt/3886738 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Pharmacy and Therapeutics, online erschienen am 29.04.2026. Verfasst von Yuta Sudo und 9 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We previously identified a strong association between seven rare DPYD variants (Ser199Asn, Ile245Phe, Thr305Lys, Glu386Ter, Ser556Arg, Ala571Asp, and Trp621Cys) and fluoropyrimidine‐related toxicity in Japanese cancer patients. Herein, we reported clinical and molecular functional analyses of these seven rare DPYD variants.

Methods

Mutant dihydropyrimidine dehydrogenase (DPD) enzymes were expressed in HEK293 cells. DPD activity was measured by quantifying dihydro‐5‐FU using high‐performance liquid chromatography–tandem mass spectrometry. DPD levels and dimerization were analyzed via western blotting and blue native PAGE. In addition, three‐dimensional (3D) structural modeling was performed to evaluate the effects of these mutations on enzyme structure and function.

Results

Transient expression of DPD variant enzymes in HEK293 cells showed that the Ser199Asn, Ala571Asp, and Glu386Ter variants caused profound reductions in activity compared to the wild type (27%, 5.0%, and undetectable, respectively), while Thr305Lys, Trp621Cys, Ile245Phe, and Ser556Arg retained partial to normal activity (49%, 58%, 118%, and 113%). The results of 3D structural analysis supported the functional findings from HEK293 cell experiments. Clinical evaluation revealed that carriers with the five variants (Ser199Asn, Ile245Phe, Glu386Ter, Ala571Asp, and Trp621Cys) presented with adverse reactions Graded 3 or higher according to the Common Terminology Criteria for Adverse Events. Retrospective assessment of DPD activity in peripheral blood mononuclear cells revealed that patients carrying Ser199Asn, Ala571Asp, or Glu386Ter exhibited reduced DPD activity, correlating with findings from HEK293 cell experiments.

Conclusions

Expression studies demonstrated that the rare DPYD variants Ser199Asn, Ala571Asp, and Glu386Ter were associated with decreased DPD enzyme activity and 5‐FU toxicity, even in the heterozygous state.

Zitieren

APA

Sudo, Y., Nakajima, Y., Yokoi, K., Yasuda, Y., Inagaki, H., Matsuoka, H., Maeda, Y., Yoshikawa, T., Ito, T., & Kurahashi, H. (2026). Functional Analysis of DPYD Variants Associated With 5‐Fluorouracil‐Based Anticancer Drug Toxicity in Cancer Patients. Journal of Clinical Pharmacy and Therapeutics, 2026(1). https://doi.org/10.1155/jcpt/3886738

Vancouver

Sudo Y, Nakajima Y, Yokoi K, Yasuda Y, Inagaki H, Matsuoka H, et al. Functional Analysis of DPYD Variants Associated With 5‐Fluorouracil‐Based Anticancer Drug Toxicity in Cancer Patients. Journal of Clinical Pharmacy and Therapeutics. 2026;2026(1). doi:10.1155/jcpt/3886738

BibTeX
@article{Sudo2026,
  author = {Sudo, Yuta and Nakajima, Yoko and Yokoi, Katsuyuki and Yasuda, Yasuaki and Inagaki, Hidehito and Matsuoka, Hiroshi and Maeda, Yasuhiro and Yoshikawa, Tetsushi and Ito, Tetsuya and Kurahashi, Hiroki},
  title = {Functional Analysis of DPYD Variants Associated With 5‐Fluorouracil‐Based Anticancer Drug Toxicity in Cancer Patients},
  journal = {Journal of Clinical Pharmacy and Therapeutics},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/jcpt/3886738}
}
Kostenlos starten →